A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
← catalyst calendarNCT05678205 · readout ≤ 253 d
Sponsored by Artiva Biotherapeutics, Inc. (industry) · ARTV — their whole pipeline →.
Phase
Phase 1/2
Status
Withdrawn
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
0actual
Sites
2
Countries
South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Corporate business decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-01 | estimated | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
Interventions
- Drug: AB-201
- Drug: Cyclophosphamide
- Drug: Fludarabine
Primary outcomes
what the primary-completion date above is the date OFSafety: incidence and severity of adverse events and serious adverse events
measured From the time of consent through End of Study (up to 18 months per patient)
Determination of Recommended Phase 2 Dose (RP2D): safety, preliminary efficacy (based on objective response rate (ORR) defined as the proportion of patients with a complete or partial response) and pharmacokinetics
measured From the time of consent through End of Study (up to 18 months per patient)
Efficacy: Objective Response Rate, defined as the proportion of patients with a complete or partial response
measured From the time of consent through End of Study (up to 18 months per patient)
Permalink · ARTV's whole pipeline · Catalyst calendar · Every registered study · What changed